What will happen once the targeted drug Sorafenib is stopped?

The initial full-dose regimen for sorafenib is 400 mg twice daily. For some patients, including the elderly or those with compromised hepatic function, the initial dose may be reduced to 400 mg daily. Treatment interruptions and dose reductions were also allowed if any patient experienced serious adverse events. Toxicity of sorafenib treatment was assessed based on adverse events. Clinical response was assessed according to criteria, based on dynamic computed tomography (CT) or magnetic resonance imaging (MRI) results obtained every 6 to 8 weeks during treatment.

Hepatocellular carcinoma (HCC) patients may exhibit molecular heterogeneity and inconsistent baseline populations. Therefore, multidisciplinary treatment may have some impact on the treatment of HCC patients at different disease stages. In a study of long-term survivors over three years who were treated with various salvage regimens during or after sorafenib, in the present study, 43 patients (61%) received additional local therapy (TACE or HAIC) or subsequent second-line targeted therapy, which helped prolong survival in these patients after sorafenib.

The original drug of sorafenib has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around 1,200 yuan. The original drug of sorafenib has also been launched overseas, and there are also generic drugs of sorafenib produced in other countries. The price of 0.2g*60 tablets produced by a Bangladesh pharmaceutical factory is around RMB 450 (the price may fluctuate due to the exchange rate). The ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.